What's in Grupo Espanol de Tumores Neuroendocrinos's pipeline?

Grupo Espanol de Tumores Neuroendocrinos has 3 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Grupo Espanol de Tumores Neuroendocrinos's portfolio?

Top competitors by shared drug class: AstraZeneca, Children's Hospital of Fudan University, China Medical University, China, Chong Kun Dang Pharmaceutical, Exelixis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/grupo-espanol-de-tumores-neuroendocrinos.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Grupo Espanol de Tumores Neuroendocrinos — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Grupo Espanol de Tumores Neuroendocrinos pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
STZ-5FU	STZ-5FU	phase 3	pyrimidine analog	thymidylate synthase	Oncology
Drug: Everolimus	Drug: Everolimus	phase 3	mTOR inhibitor	mTORC1	Oncology
177Lu-edotreotide	177Lu-edotreotide	phase 3	Radioligand therapeutic; somatostatin receptor agonist	Somatostatin receptor 2 (SSTR2)	Oncology

Therapeutic area mix

Oncology · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 1 shared drug class
Children's Hospital of Fudan University · 1 shared drug class
China Medical University, China · 1 shared drug class
Chong Kun Dang Pharmaceutical · 1 shared drug class
Exelixis · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
H. Lee Moffitt Cancer Center and Research Institute · 1 shared drug class
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Grupo Espanol de Tumores Neuroendocrinos:

Cite this brief

Drug Landscape (2026). Grupo Espanol de Tumores Neuroendocrinos — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/grupo-espanol-de-tumores-neuroendocrinos. Accessed 2026-05-17.